https://insightsemerge.com/press-releases/johnson-and-johnson-announces-icotyder-icotrokinra-delivers-significant-improvement-inInsights Emergeen2026-11-07T15:18:46.079ZJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://insightsemerge.com/press-releases/hengrui-pharma-and-braveheart-bio-present-data-from52-week-open-label-extension-of-phaseInsights Emergeen2026-11-06T20:36:29.123ZHengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 https://insightsemerge.com/press-releases/perspective-therapeutics-presents-promising-212pblapemelanotide-zapixetar-vmt01Insights Emergeen2026-11-06T17:15:31.634ZPerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 https://insightsemerge.com/press-releases/inimmune-presents-late-breaking-phase-1-ini-4001-results-demonstrating-on-target-immuneInsights Emergeen2026-11-06T15:02:31.916ZInimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026 https://insightsemerge.com/press-releases/combinations-of-ioncturas-roginolisib-revert-immune-suppression-in-immunotherapyInsights Emergeen2026-11-06T14:19:54.333ZCombinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC https://insightsemerge.com/press-releases/perspective-therapeutics-presents-encouraging-incremental-data-and-analyses-from-phaseInsights Emergeen2026-11-06T12:23:47.892ZPerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs https://insightsemerge.com/press-releases/bausch-healths-gastroenterology-business-salix-to-present-new-data-on-cirrhosis-trendsInsights Emergeen2026-11-06T12:20:25.000ZBausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 https://insightsemerge.com/press-releases/bio-thera-announces-nmpa-approval-of-bat2506-the-first-golimumab-biosimilar-approved-inInsights Emergeen2026-11-06T12:17:33.401ZBio-Thera Announces NMPA Approval of BAT2506, the First Golimumab Biosimilar Approved in China